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A Double-Blind Comparison of Orally
Administered Ciramadol and Codeine for
Relief of Postoperative Pain
David F. Graf, MD, Sujit K. Pundit, MD, Sarla P. Kothary, MBBS, DA,
and George H. Freeland, MD
Ciramadol, a new analgesic with mixed narcotic agonist-antagonist actions, was com-
pared with codeine and placebo in a double-blind study in 343 patients with postoperative
pain. The patients received a single oral dose of either 30 or 60 mg of ciramadol, 60 mg of
codeine, or placebo. As indicated by three efficacy measures (verbal and visual analog
pain scores and pain relief scores), the three active treatments were superior to placebo in
relieving pain, and 30 and 60 mg of ciramadol generally were equivalent and superior,
respectively, to 60 mg of codeine. The group who took 60 mg of ciramadol had a
significantly (P < .05) lower cumulative remedication frequency than that for the other
three groups and the highest proportion of satisfactory evaluations by patients and
physicians. There was no statistically significant difference in the incidence of side effects
(4% to 11%) among the treatment groups. Demonstrated safety and efficacy suggest a role
for ciramadol in the treatment of postoperative pain.
C iramadol, [1R-[la (R*),2]J3[(dimethylamino)(2
hydroxycyclohexyl)methyl]phenol, is an analgesic
with the pharmacologic profile of a mixed narcotic
agonist-antagonist.1 It has been shown to be an effec-
tive analgesic in rodents and primates when adminis-
tered subcutaneously, intraperitoneally, orally, and
intramuscularly. In human subjects, orally adminis-
tered ciramadol is rapidly absorbed, with plasma
levels reaching a maximum concentration between
one and tWo hours after drug administration. Its
elimination half-life is four to five hours.2
Clinical studies have shown that in oral doses of 20
and 60 mg, ciramadol was effective in the treatment of
chronic pain due to cancer,3’4 and the analgesic effect
was dose dependent and superior to that of placebo.4
Single oral doses of 30 and 90 mg of ciramadol also
were superior to 60 mg of codeine for relief of
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moderate to severe cancer pain.5 Ciramadol has been
found to be safe and effective in the treatment of
postepisiotomy and postoperative pain in oral doses of
15 to 60 mg.6-8 Ciramadol 60 mg provided relief of
postoperative pain that was superior and longer last-
ing than that provided by 50 mg of pentazocine.8 In
the treatment of moderate and severe postepisiotomy
pain, 15 mg, 30 mg, and 60 mg of ciramadol were
superior to placebo and to 60 mg of codeine in
producing analgesia for up to six hours.7 Ciramadol
and codeine, however, have not been compared in
the treatment of postoperative pain.
The present study was designed to compare two
oral doses of ciramadol with codeine and a placebo in
patients with moderate or severe postoperative pain.
METHODS
Patients of either sex, any race, and physical status I
or II, as defined by the American Society of Anesthe-
siologists,9 who were experiencing moderate to severe
postoperative pain for which the attending surgeon
had ordered oral analgesics, were eligible for inclu-
sion in the study. They had to be between the ages of
18 and 65 years and weigh between 100 and 210 lb.
Those who had a history of chronic analgesic or
ORAL CIRAMADOL
CLINICAL RESEARCH: ANALGESIC DRUGS 591
tranquilizer use or known drug dependence, were
sensitive to narcotics or narcotic antagonists, were
taking interfering or potentially interacting medica-
tions, had received an analgesic within three hours of
the start of the study, or were unable to communicate
meaningful information about their pain were
excluded. Pregnant women also were excluded. Insti-
tutional review board approval was granted, and
written informed consent was obtained from each
patient before surgery.
The six-hour study was conducted at separate sites
by two trained medical investigators using a common
protocol. The study was double blind; patients were
assigned randomly to one of four treatment groups
and received a single oral tablet containing either 30
mg of ciramadol, 60 mg of ciramadol, 60 mg of
codeine, or placebo. All study drugs were identical in
appearance and were administered between three
and 48 hours after surgery. Efficacy and safety assess-
ments of the test medications were made immediately
before drug administration (baseline) and at 30
minutes and 1, 2, 3, 4, 5, and 6 hours after administra-
tion.
Three scales were used during the study to record
the patients’ subjective evaluations of drug efficacy at
each observation time. Pain intensity was rated ver-
bally as none (0), mild (1), moderate (2), or severe (3).
The patients also rated their pain intensity on a visual
scale, consisting of a 100-mm line with one end
representing no pain and theother representing worst
pain ever felt. Measurement of each patient’s mark on
the line resulted in a pain analog intensity score
between zero and 100. Pain relief was assessed as
worse pain (-1), no relief (0), a little relief (1), mod-
erate relief (2), a lot of relief (3), or complete relief (4).
Several measures of analgesic efficacy were
derived from the pain intensity and relief scores. Pain
intensity differences (PIDs) and pain analog intensity
differences (PAIDs) were calculated by subtracting
the respective pain intensity score at each observation
time from the baseline intensity score. Furthermore,
the weighted PID and PAID scores for each patient at
each evaluation (i.e., each score multiplied by the
fraction of an hour since the last observation) were
added to obtain the summed pain intensity difference
(SPID) and the summed pain analog intensity differ-
ence (SPAID), respectively. Total pain relief (TOT-
PAR) scores were obtained by adding the weighted
pain relief scores at each evaluation (i.e., each score
multiplied by the fraction of an hour since the last
observation).
At each observation time, patients who required
additional analgesic medication were withdrawn
from the study and given standard analgesic medica-
tion. According to the protocol advocated by Lasa-
gna1#{176}and Houde and associates,11 these patients were
assigned efficacy scores corresponding to baseline
pain intensity or to no relief after they were given
additional medication.
The degree of sedation was rated by the investiga-
tor at each observation time as none, mild, moderate,
or marked. Vital signs were recorded at each observa-
tion time. All adverse experiences reported by the
patients or observed by the investigator were record-
ed and rated by the investigator as definitely, proba-
bly, possibly, or not related to the drug treatment.
At the end of the six-hour study period, patients
were asked to rate their overall drug experience as
excellent, good, fair, or poor. The investigator also
rated each patient’s overall response to the study drug
as satisfactory or unsatisfactory, after reviewing the
onset and duration of analgesia and the presence or
absence of adverse effects.
The demographic variables of a continuous nature
were compared among the groups by a one-way
analysis of variance, supplemented by the Student-
Newman-Keuls test for pairwise comparisons.12 Cate-
gorized baseline assessments and the frequencies of
adverse effects were compared among the treatment
groups, using the chi-square test supplemented by
Fisher’s exact test for pairwise comparisons when
appropriate. Efficacy variables of an ordinal or nomi-
nal nature were analyzed by the generalized Coch-
ran-Mantel-Haenszel approach using marginal ridit
scores with baseline scores and investigator as covar-
iables.13 Comparison of the PAID scores and vital
signs among treatment groups were made using an
analysis of covariance. The absence of statistically
significant investigator-by-therapy interactions was
verified by a two-way model. Changes within groups
in vital signs were analyzed with a paired t test.
RESULTS
Patient Population
The study population included 343 patients: 83
received 30 mg of ciramadol, 87 received 60 mg of
ciramadol, 84 received 60 mg of codeine, and 89
received a placebo. Of the total patient population,
203 (59%) were men, 323 (94%) were white, 18 (5%)
were black, and two (1%) were of other races. Age
TABLE
*Higher scores indicate greater pain relief. Data are presented as
mean ± standard error of the mean.
tValue is significantly (P <.05) higher than placebo.
Figure 1. Mean pain relief scores for the four treatment
groups during the six-hour observation period. Higher
scores indicate greater pain relief.
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ranged from 18 to 65 years (mean age, 36 years) and
weight ranged from 91 to 253 lb (mean weight, 160 Ib).
Initial pain intensity was moderate for 224 patients
(65%) and severe for 119 patients (35%). Statistical
analysis revealed no significant differences among
the treatment groups with respect to demographic
characteristics and initial pain intensity. Thus, subse-
quent analyses included data from all patients In each
treatment group regardless of initial pain intensity.
Pooling of the data collected at the two study sites
seemed justified because each Investigator used iden-
tical procedures for patient admission and assignment
to treatment groups, drug administration, and obser-
vation, as well as identical criteria for efficacy and
safety evaluation. Moreover, no major inconsistencies
were found in the results obtained at the two investi-
gational sites, nor were there any statistically signifi-
cant effects for investigator or investigator-by-therapy
interactions. Thus, the study results represent pooled
data from the two populations.
Twenty-seven patients were excluded from the
efficacy evaluation, 23 because they did not fulfill the
inclusion criteria and four because they vomited
within 30 minutes of receiving the test drug. Two of
the 27 patients were sedated heavily at the time of
drug administration and also were excluded from the
sedation analysis, and one patient was a class III
surgic#{233}lrisk and thus was excluded from both the
sedation and vital signs analyses. The patients evalu-
ated for efficacy were comparable statistically to the
total study group. All patients were included in the
safety evaluation.
Efficacy Evaluations
Throtighout the six-hour observation period, consis-
tentl’ higher mean scores, indicating greater pain
relief, were noted for the three active therapy groups
as compared with those for the placebo group. Statis-
tically significant advantages over placebo in the PID
(not shown) and PAID scores (Table) as well as the
pain relief scores (Figure 1) were observed for the 60
mg ciramadol group at one through six hours, for the
30 mg ciramadol group at two through five hours, and
for the codeine group at one through four hours. In
general, scores in the 60 mg ciramadol group tended
to be higher than those in the 30 mg ciramadol and the
60 mg codeine groups. Efficacy scores for the 30 mg
ciramadol group and the 60 mg codeine group gener-
ally were similar with a slight advantage for the
codeine group during the first hour and for the 30 mg
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ciramadol group at three through six hours. A statisti-
cal advantage was observed for the 60 mg ciramadol
group compared with the codeine group in pain relief
scores at three through six hours and in PID scores at
three, five, and six hours. Other pairwise differences
in efficacy scores between active treatment groups
were not statistically significant.
Effective pain relief, as measured by a pain relief
score of moderate or greater, was reported at some
time during the observation period by 65% of the
patients treated with 30 mg of ciramadol, 63% of those
0
0
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Figure 2. Cumulative pain scores for the six-hour observa-
tion period. Higher scores indicate greater pain relief.
SPID = summed pain intensity difference; TOTPAR = to-
tal pain relief; SPAID = summed pain analog intensity
difference.
treated with 60 mg of ciramadol, 61% of those treated
with 60 mg of codeine, and 47% of those treated with
placebo. Significantly higher (P < .05) proportions of
patients in the 30 mg ciramadol group between two
and six hours, in the 60 mg ciramadol group between
one and six hours, and in the codeine group at one
and two hours had effective pain relief than those in
the placebo group. In addition, between three and six
hours, the proportion of patients with effective relief
was significantly higher (P < .05) in the 60 mg cira-
madol group than in the codeine group.
The cumulative six-hour efficacy scores (SPID,
TOTPAR, SPAID) were significantly higher (P < .05)
for the three active treatment groups than for the
placebo group (Figure 2). The highest scores on all
three scales were seen in the 60 mg ciramadol group.
Scores for the 30 mg ciramadol group and the 60 mg
codeine group were generally similar, although slight-
ly higher scores were reported for the 30 mg cirama-
dol group.
At six hours, 55% of patients in the 30 mg ciramadol
group, in the 60 mg ciramadol group, 70% in the
codeine group, and 79% in the placebo group had
requested additional analgesic medication. The
cumulative remedication rates for the 30 mg and 60
mg ciramadol groups, but not the codeine group, were
significantly lower (P < .001) than that for the placebo
group. At six hours, the remedication rates for the
ciramadol groups were also significantly lower
(P < .05) than that for the codeine group.
Safety Evaluation
The majority of patients were either not sedated or
only mildly sedated at baseline. Some increase in
mean sedation level was seen in each group after drug
administration, with slightly larger increases (to a
mean level near mild) in the active treatment groups.
There was no statistically significant difference in
sedation scores among the active treatment groups at
any time.
No statistically significant changes in systolic or
diastolic blood pressure were noted within or among
the treatment groups. Statistically significant
decreases from the baseline pulse rate (by 1.7 to 2.1
beats/mm) were observed in the 60 mg ciramadol
group at 30 minutes and one hour. Although mean
respiratory rates were significantly lower (P < .05)
than baseline values at various observation times in
all four treatment groups (by 0.8 to 1.3 respirations!
mm), these changes were considered clinically un-
important. No clinically significant respiratory
depression was observed.
Adverse experiences considered to be at least pos-
sibly drug related were reported by nine (11%)
patients in the 30 mg ciramadol group, six (7%) in the
60 mg ciramadol group, three (4%) In the 60 mg
codeine group, and five (6%) in the placebo group.
The most commonly reported adverse effects were
nausea (1% to 7%), vomiting (0% to 6%), and dizzi-
ness (0% to 3%). No statistically significant differ-
ences in the frequencies of adverse effects were noted
among the four treatment groups.
Overall Evaluations of Test Medications
The physician rated the test medication as satisfactory
for 52% of patients in the 30 mg ciramadol group, 64%
in the 60 mg ciramadol group, 54% in the 60 mg
codeine group, and 31% in the placebo group. Overall
ratings of good or excellent were given by 52% of
patients treated with 30 mg of ciramadol, 61% given
60 mg of ciramadol, 51% treated with 60 mg of
codeine, and 23% of the placebo-treated patients. A
significant (P < .01) advantage over placebo was
noted in both the physician and patient evaluations
for 30 and 60 mg of ciramadol and 60 mg of
codeine.
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DISCUSSION
The search for analgesic agents with efficacy similar
to that of the narcotic agonists and reduced depen-
dence liability has resulted in the development of the
mixed narcotic agonist-antagonist analgesics. In this
study, ciramadol, a new analgesic with a mixed
agonist-antagonist profile, was superior to placebo for
relief of moderate to severe postoperative pain. The
analgesic effect observed in this study after ciramadol
administration is consistent with the results of other
ciramadol studies.4’6’8 Moreover, efficacy scores and
overall evaluations were consistently higher for
patients who received 60 mg of ciramadol than for
patients in the other three treatment groups; the scores
and ratings for patients who received 30 mg of
cirainadol and 60 mg of codeine generally were
similar. Not only did the 60 mg dose of ciramadol
provide more effective pain relief than codeine for a
greater proportion of patients, but both doses of
ciramadol resulted in a longer duration of analgesia
than did codeine, as indicated by significantly lower
remedication rates and higher efficacy scores at later
time periods. The duration of action for ciramadol
observed in this study is consistent with a reported
half-life of four to five hours.3
In addition to having an analgesic efficacy that was
comparable to that of codeine and a duration of action
that was longer than that of codeine, ciramadol
administration was associated with a low incidence of
mild side effects that was similar to that for codeine.
The type, severity, and incidence of adverse effects
observed among ciramadol-treated patients were sim-
ilar to those reported from other clinical ciramadol
studies.4’6’8 Of particular importance for postsurgical
patients, there were no changes in respiratory rate
and clinically significant respiratory depression
among ciramadol- and codeine-treated patients.
It is interesting that these findings are not consistent
with those of an earlier study in which intramuscular-
ly administered ciramadol was reported not to be
effective in relieving postoperative pain.14 The inves-
tigators attributed this to a predominance of the
narcotic antagonist effect in patients with prior nar-
cotic exposure. This explanation is plausible, particu-
larly in reference to a population of patients who have
received multiple doses of narcotic agonists. Further-
more, it suggests that prior exposure to narcotics is an
important consideration in the patient’s history for the
effective use of mixed agonist-antagonist analgesics.
In the present study, however, there were no explicit
restrictions on the amount of narcotics that had been
used, either intraoperatively or postoperatively,
before patient enrollment. Indeed, almost every
patient receiving ciramadol had been treated previ-
ously with a pure narcotic agonist, and nearly 50% of
the patients in the ciramadol groups had received
three or more doses of narcotics before enrollment.
This suggests that the effective use of orally adminis-
tered ciramadol is not limited to the treatment of
patients who are entirely without previous narcotic
exposure. The dissimilar results of the two studies
could be due to differences in the dosages of previous
narcotic agents, which would tend to be higher for
patients who require parenteral analgesics, or to
differences in the timing of prior narcotic administra-
tion relative to the subsequent administration of
ciramadol.
This study has demonstrated the safety and efficacy
of ciramadol for the treatment of moderate and severe
postoperative pain. As measured by standard analge-
sia scales and overall evaluations, 30 mg and 60 mg of
ciramadol were found to be equal and superior to 60
mg of codeine, respectively. A statistical advantage
was found for ciramadol with respect to codeine at the
later observation times, indicating a longer duration
of analgesic effect.
The results of this study indicate that ciramadol is a
promising analgesic for use in the treatment of mod-
erate and severe postoperative pain and that further
clinical investigation is warranted.
The authors wish to acknowledge G.S. Littman, PhD, and
his colleagues for statistical analyses and V.L. Pascucci,
PharmD, for editorial assistance.
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Status Report From the Council on Clinical
Pharmacology: November 1985
Six years ago, duly appointed representatives of the American
College of Clinical Pharmacology (ACCP), the American Society for
Clinical Pharmacology and Therapeutics (ASCPT), and the Ameri-
can Society for Pharmacology and Experimental Therapeutics
(ASPET) formed the Council on Clinical Pharmacology to explore
the possibilities of seeking clinical board recognition of clinical
pharmacology.
After intensive discussion and careful consideration of all avail-
able options, the Council on Clinical Pharmacology concluded that
our first option would be to seek a “Certificate of Special Compe-
tency” in clinical pharmacology for those clinical pharmacologists
who hold board certification in internal medicine from the Ameri-
can Board of Internal Medicine (ABIM) within the American Board
of Medical Specialties.
On May 13, 1983 the Council on Clinical Pharmacology submit-
ted to the ABIM a detailed request of a board certification in
clinical pharmacology. The ABIM graciously acknowledged our
application as carefully prepared-one that followed a thoughtful,
informed approach. However, after additional correspondence and
careful consideration, our request was declined by the ABIM on
October 2, 1984.
Although the ABIM clearly took no position on alternatives, they
suggested that we examine the model used by geneticists in
establishing the American Board of Medical Genetics in 1980. That
board, independent of the American Board of Medical Specialties,
regularly examines and certifies geneticists.
We understand that the American Board of Medical Genetics.
mc, has been well received and is a widely respected and efficient
mechanism for certifying geneticists.
During a very productive meeting on December 8, 1984, the
Council on Clinical Pharmacology unanimously agreed to recom-
mend to our three sponsoring societies (ACCP, ASCPT, and
ASPET) that we form an independent Board of Clinical Pharmacol-
ogy to provide a certifying process for qualified clinical pharmacol-
ogists.
Subsequently, ACCP. ASCPT. and ASPET each agreed to fully
support this recommendation to form an independent board and
each society provided “seed” funds to initiate this process.
Several important working groups have been established for the
purposes of developing an independent board of clinical pharma-
cology, developing a certifying examination, and for improving
training in clinical pharmacology. The working groups are as
follows: “Financial Resources for Establishing “Board”-Drs.
Joseph R. Bianchine and Kazuo K. Kimura; “Establishment of a
Legal Framework for the “Board”-Drs. Duncan E. Hutcheon,
David T. Lowenthal, Joseph R. Bianchine, and Benjamin Calesnick;
“Credentialing of Candidates for the Board-Certifying Examina.
tion”-Drs. Kazuo K. Kimura. Thomas P. Gibson, Joseph R. DiPal-
ma, and Benjamin Calesnick; “Development of a Board-Certifying
Examination”-Drs. Joseph R. DiPalma, W. Leigh Thompson,
Harold F. Hailman, Donald S. Robinson. Darrell R. Abernethy, and
Alexander Shephard; and “Accreditation of Training Programs”-
Drs. D. Craig Brater, Terrence F. Blaschke, David T. Lowenthal and
Carl C. Peck.
It is anticipated that the first certifying examination administered
by the board will be given in the spring of 1987.
Suggestions, comments, and offering of assistance from interest-
ed individuals will be greatly appreciated, especially during the
remainder of 1985, since it is anticipated that the actual formation
of this board and the implementation of the certifying process will
be accomplished early in 1986.
Membership of the Council on Clinical Pharmacology
Joseph Ft. Bianchine, MD, PhD
(Chairman)
Terrence F. Blaschke, MD
D. Craig Brater, MD
Benjamin Calesnick, MD
Harold Ft. Dettelbach, PhD
Joseph Ft. DiPalma, MD w. Leigh Thompson, MD, PhD
William Forrest, MD Richard M. Weinshilboum, MD
Thomas P. Gibson, MD Andrew Whelton, MD
Harold F. Hailman, MD, PhD
